CytomX Therapeutics Inc (CTMX)

NASDAQ
5.190
-0.040(-0.76%)
After Hours
5.220
+0.030(+0.578%)
- Real-time Data
  • Volume:
    550,814
  • Bid/Ask:
    5.070/5.220
  • Day's Range:
    5.060 - 5.270
  • Type:Equity
  • Market:United States
  • ISIN:US23284F1057
  • CUSIP:00023284F105

CTMX Overview

Prev. Close
5.23
Day's Range
5.06-5.27
Revenue
66.42M
Open
5.1
52 wk Range
4.28-10.05
EPS
-1.18
Volume
550,814
Market Cap
338.16M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
710,143
P/E Ratio
-
Beta
0.71
1-Year Change
-29.86%
Shares Outstanding
65,157,003
Next Earnings Date
Nov 09, 2021
What is your sentiment on CytomX Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

CytomX Therapeutics Inc News

CytomX Therapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyBuyNeutralStrong Sell
Technical IndicatorsStrong BuyBuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyBuyStrong Sell

CytomX Therapeutics Inc Company Profile

CytomX Therapeutics Inc Company Profile

Employees
144

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.

Read More
  • fair value = 0.7dollar/share
    0
    • drop it as much as u can lol
      0
      • Only going up from here -
        0
        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.